Home > Boards > US Listed > Biotechs >

Keryx Biopharmaceuticals, Inc (KERX)

Add KERX Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/19/2018 12:06:17 PM - Followers: 137 - Board type: Free - Posts Today: 0




Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both multiple myeloma and refractory advanced colorectal cancer, and in Phase 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing ZerenexTM (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of ZerenexTM in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is pending commencement under an SPA agreement with the FDA. Keryx also actively engages in business development activities that include seeking strategic relationships for its product candidates, as well as evaluating compounds and companies for in-licensing or acquisition.

Keryx is headquartered in New York City.

Keryx Biopharmaceuticals is traded on the Nasdaq Stock Market under the symbol "KERX."

Corporate Headquarters


Keryx Biopharmaceuticals, Inc.
750 Lexington Ave. - 20th Floor
New York, NY 10022
Phone: 1-212-531-5965
Fax: 1-212-531-5961
Contact Email
Investor Relations
Business Development
Clinical Trials
Employment Opportunities

Company Website


Product candidate Target indication Development status
ZerenexTM (ferric citrate) Hyperphosphatemia in patients with end-stage renal disease U.S. Phase 3 program ongoing under SPA; 
Japan Phase 3 program ongoing by sublicensee (JT and Torii)


Recent News:


Gallery views:


                KERX - Daily Candlesticks  

Analyst's estimates and ratings:


The most recent Quarterly (10-Q)

Do your own DD and trade smart.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
KERX News: Keryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA Congr... 04/19/2018 09:00:00 AM
KERX News: Keryx Biopharmaceuticals Receives 2018 Corporate Innovator Award from the National Kidney Foundation 04/11/2018 09:11:29 AM
KERX News: Keryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial of Auryxia® (ferric citrate) for Iron Deficien... 04/04/2018 08:00:00 AM
KERX News: Confidential Treatment Order (ct Order) 04/03/2018 12:31:03 PM
KERX News: Statement of Changes in Beneficial Ownership (4) 03/22/2018 05:32:42 PM
News News Alert: Keryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA Congr... 04/19/2018 09:00:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#3239   Almost forget... FredKerx 04/19/18 12:06:17 PM
#3238   Well, at least my last post was not FredKerx 04/14/18 11:04:54 AM
#3237   As you know, consider there’s a connection between FredKerx 04/13/18 06:51:27 AM
#3236   Folks, you might remember a couple of post FredKerx 04/12/18 03:48:05 PM
#3235   Nice day yesterday! Hopefully the positive momentum can fsulevine 04/12/18 08:20:13 AM
#3234   * * $KERX Video Chart 04-11-18 * * ClayTrader 04/11/18 05:26:07 PM
#3233   Fred, mein Arschloch tut weh. LOL! KarlDieGlatze 04/11/18 03:37:13 PM
#3232   @AnfuhreMitwut There’s only ONE hypo, and it’s SNY FredKerx 04/11/18 03:17:02 PM
#3231   @AnfuhrerMitwut Left me thinking with your potential extended FredKerx 04/10/18 09:31:40 PM
#3230   IMO, the Yoshka/gwells-IR contact scenario being played-out on FredKerx 04/10/18 11:04:55 AM
#3229   continued...(would not let me post on Yahoo) FredKerx 04/09/18 08:27:22 AM
#3228   @Michele Hello Michele, always a pleasure to read FredKerx 04/08/18 04:57:52 AM
#3227   Fellow investors, once again, we the common shareholders FredKerx 04/03/18 04:09:32 PM
#3226   Oh, what a beauty of a post this FredKerx 04/02/18 10:59:43 AM
#3225   Yes Keryx executive management... FredKerx 03/31/18 02:42:27 PM
#3224 FredKerx 03/30/18 06:11:01 PM
#3223   Fred so you think KERX merge coming, KERX Tate 03/29/18 09:57:13 AM
#3222   Folks, yesterday, in my reply to Michele, wrote FredKerx 03/29/18 09:37:41 AM
#3221   Folks, “hooligan” Yoshka’s report from a much touted FredKerx 03/29/18 02:05:05 AM
#3220   Oh ohhh, my last post on Yahoo Keryx FredKerx 03/27/18 07:29:40 AM
#3219   Again, below is list of VP’s, Senior Directors, FredKerx 03/27/18 05:58:18 AM
#3218   @AnfuhrerMitwut There is one weak spot to hypothetical FredKerx 03/25/18 02:38:00 PM
#3217   Link at bottom is for article titled, “Net FredKerx 03/25/18 08:06:34 AM
#3216   Here’s another market study, yet they can’t put FredKerx 03/23/18 12:15:58 PM
#3215   If they have a person on the board, fsulevine 03/22/18 12:37:23 PM
#3214   As per poster Yoshka’s/gwells bilateral high level talks FredKerx 03/22/18 08:10:35 AM
#3213   As per poster Yoshka’s/gwells bilateral high level talks FredKerx 03/22/18 07:19:31 AM
#3212   In a follow-up post, poster Yoshka/gwells goes on FredKerx 03/22/18 06:19:55 AM
#3211   Fellow investors, just so you understand Auryxia’s blockbuster FredKerx 03/18/18 09:46:51 PM
#3210   Fellow investors, in my opinion, questions arise concerning FredKerx 03/18/18 05:00:29 PM
#3209   The European Medicines Agency (EMA) approved Fexeric with FredKerx 03/18/18 04:58:00 PM
#3208   FEXERIC labeling AND package leaflet (Website: FredKerx 03/18/18 08:20:42 AM
#3206   As put forth previously, hypothetical scenario considers “a FredKerx 03/17/18 12:40:36 PM
#3205   As put forth previously, hypothetical scenario considers “a FredKerx 03/17/18 12:40:05 PM
#3204   You see, folks, RMTI founder, CEO, and owner FredKerx 03/16/18 01:30:39 PM
#3203   The following, the complete hypothetical scenario, the ultimate FredKerx 03/15/18 12:42:03 PM
#3202   CALL AMGEN, Fred. KarlDieGlatze 03/12/18 03:47:35 PM
#3201   Notice the unusual mentions here today of Baupost FredKerx 03/12/18 03:33:03 PM
#3200   Fred, Is Fidelity in the toxic mix of KarlDieGlatze 03/11/18 01:06:37 PM
#3199   We recently found out that Norges Bank Investment FredKerx 03/10/18 07:10:41 AM
#3198   Yesterday I posted that Blackrock Inc. filed (January FredKerx 03/09/18 08:02:58 PM
#3197   Hi Amy, KarlDieGlatze 03/09/18 03:11:06 PM
#3196   Confirmation has been given officially that "Mr. Chambers KarlDieGlatze 03/09/18 01:41:57 PM
#3195   “Cleaning the floor with me? Is that what FredKerx 03/09/18 12:06:25 PM
#3194   @Dave Let’s see, you start peddling the go-it-alone FredKerx 03/09/18 10:28:25 AM
#3193   Fellow investors, in GENERAL, let’s review key points FredKerx 03/09/18 07:49:52 AM
#3192   @Carmen At this time, projected, they have some FredKerx 03/07/18 04:38:28 PM
#3191   Found another Senior Manager, 3 Manager level, and FredKerx 03/07/18 03:36:11 PM
#3190   Below list of 50 (as per zoominfo) of FredKerx 03/07/18 06:37:32 AM
#3189   Fred, sind deine Anwälte mit angehaltenem Atem bereit KarlDieGlatze 03/06/18 10:37:52 AM